As part of its overall efforts to address compounded drugs, the U.S. Food and Drug Administration today released a draft “Guidance for Industry (GFI) #230, Compounding Animal Drugs from Bulk Drug Substances.” Current law does not permit compounding of animal drugs from bulk drug substances, but the FDA recognizes that there are limited circumstances when an animal drug compounded from bulk drug substances may be an appropriate treatment option. FDA’s GFI #230 outlines specific conditions under which the agency generally does not intend to take action against state-licensed pharmacies, veterinarians, and facilities registered asoutsourcing facilities when drugs are compounded for animals from bulk drug substances. [Source: FDA Press Release, May 18, 2015]

The Drug Quality and Security Act, which amended the human drug compounding provisions in the Federal Food, Drug, and Cosmetic Act (FD&C Act) and created a new section 503B of the FD&C Act for outsourcing facilities, provides certain statutory exemptions for compounded human drugs, but the law does not apply to drugs compounded for animal use.

There are circumstances where there is no approved drug that can be used or modified through compounding to treat a particular animal with a particular condition. In those limited situations, an animal drug compounded from bulk drug substances may be an appropriate treatment option.

“This draft guidance, once finalized, will help to ensure that animal drugs compounded from bulk drug substances are available for patient care without compromising the animal drug approval process or jeopardizing the safety of the food supply,” said Bernadette Dunham, D.V.M., Ph.D., director of the FDA’s Center for Veterinary Medicine.

In addition, the FDA is developing a list of bulk drug substances that facilities registered as outsourcing facilities under section 503B can use to compound drugs for an individual animal patient or veterinarian office use under specified conditions. In a separate Federal Register notice, the FDA is requesting public input on which bulk drug substances should be placed on this list.

The agency also withdrew Compliance Policy Guide Section 608.400 Compounding of Drugs for Use in Animals because it is no longer consistent with the FDA’s current thinking on these issues.

The draft guidance is available for public comment for 90 days from the date of publication of the notice of availability in the Federal Register. The public also has 90 days to submit nominations for the list of bulk drug substances that may be used by outsourcing facilities to compound drugs.

Electronic comments should be submitted to http://www.regulations.gov. Written comments should be submitted to the Division of Dockets Management, (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Room 1061, Rockville, MD 20852.